FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557864216> ?p ?o ?g. }

• W2557864216 abstract "Abstract CY and FLU are chemotherapeutic agents often used in RIC regimens. RIC regimens may yield lower transplant related complications and toxicities as compared to myeloablative conditioning. However TRM at 12 months still approximates 30%. We previously reported that high F-ara-A (active metabolite of FLU) exposure was associated with more TRM at a FLU dose of 40 mg/m2, but the relationship is unknown at lower doses. Similarly, phosphoramide mustard (PM, the active metabolite of CY) may influence clinical outcomes. Thus we studied the relationship between clinical outcomes and systemic exposure of F-ara-A at lower doses and PM. Forty adults undergoing allogeneic RIC HCT were prospectively studied from March 2013 to May 2014. All patients received FLU, CY and TBI as conditioning and cyclosporine or sirolimus, plus mycophenolate for posttransplant immunosuppression. Median age was 62 years (21-72). 22 were male and 18 female. The stem cell sources were sibling or unrelated donor PBSC (n=22, 55%), cord blood (n=13, 32.5%) or bone marrow (n=5, 12.5%). CY 50mg/kg was administered IV over 2 hrs on day -6. Pharmacokinetic samples were obtained at predose and 2, 4, 6, 21, 24 and 45 hrs after the end of infusion. PM was derivatized with diethyldithiocarbamate and measured by ultraviolet detection with HPLC. PM area under the curve (AUC0-last), AUC0-6 and AUC0-24 were calculated using non-compartmental methods (Phoenix WinNonlin Professional 6.3). Fludarabine dosing was 30 mg/m2/d (n=35), 32 mg/m2/d (n=1), 35 mg/m2/d (n=2) and 40 mg/m2/day (n=2) x 5 doses depending on protocol and was administered IV over 1 hr on days -6 to -2. In addition, F-ara-A troughs were obtained at 24 hours after the start of the first infusion on day -6 and 24 hours after start of 2nd infusion. F-ara-A quantification was performed using HPLC-UV. TRM was defined as death due to any cause other than relapse or disease progression. GVHD was staged and graded according to the standard GVHD criteria based on clinical and pathological criteria Recursive partitioning regression analysis was used to determine optimal cut points for PM and F-ara-A pharmacokinetic measures towards TRM at day 100, 6 months and 12 months and the incidence of acute graft vs host disease (GVHD). The cumulative incidence of engraftment, TRM and acute GVHD (II-IV and III-IV) was calculated using death prior to event as a competing risk. The proportional hazards model of Fine and Gray was used to assess the association of F-ara-A exposures towards TRM, acute GVHD and engraftment. The incidence of TRM at day 100 was 13%, 20% at 6 months and 47% at 12 months. The incidence of grades 2-4 and 3-4 acute GVHD was 39% and 25%. In univariate analysis, day 100 TRM risk was significantly higher in patients with a PM AUC0-24 ≥85 ug-hr/ml (relative risk (RR) 36%, [95% CI 9-64%]) vs. AUC0-24 <85 ug-hr/ml (4% [0-11%] (p<0.01). Risk of TRM at 6 months was also associated with a PM AUC0-24 ≥85 ug-hr/ml (47% [17-77%]) vs. <85 ug-hr/ml (14% [0-28%]) (p=0.02) while there was no effect of AUC0-24 on 12 month TRM. Patients with F-ara-A trough concentration after the second dose ≥75 ng/ml had significantly higher risk of day 100 TRM as compared to patients in whom F-ara-A was <75 ng/mL (33% [4-63%] vs 7% [0-15%])(p=0.01). F-ara-A troughs were not associated with TRM at 6 and 12 months. PM and F-ara-A exposures did not influence risks of acute GVHD. Engraftment rates were high (93%, CI 82-99%) so an insufficient number of failure events were available for evaluation. Higher PM exposures were associated with increased risk of TRM at day 100 and 6 months. Higher F-ara-A exposures were associated with greater risk of TRM at day 100. No associations were observed towards acute GVHD. These data for the first time show that TRM is associated with high PM exposure. These data also support our earlier findings that overexposure to F-ara-A may be harmful in RIC regimens. Multivariate models adjusting for other important clinical factors will be evaluated as enrollment continues to a larger cohort. In the future predictive pharmacokinetic models may be beneficial in personalizing fludarabine and cyclophosphamide doses. Disclosures No relevant conflicts of interest to declare." @default.
• W2557864216 created "2016-12-08" @default.
• W2557864216 creator A5001646801 @default.
• W2557864216 creator A5008157848 @default.
• W2557864216 creator A5010717307 @default.
• W2557864216 creator A5014184551 @default.
• W2557864216 creator A5037368786 @default.
• W2557864216 creator A5040328429 @default.
• W2557864216 creator A5061692821 @default.
• W2557864216 creator A5070132319 @default.
• W2557864216 creator A5074721836 @default.
• W2557864216 date "2014-12-06" @default.
• W2557864216 modified "2023-09-27" @default.
• W2557864216 title "Association of Cyclophosphamide (CY) and Fludarabine (FLU) Pharmacokinetics with Treatment Related Mortality (TRM) after Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT)" @default.
• W2557864216 doi "https://doi.org/10.1182/blood.v124.21.1153.1153" @default.
• W2557864216 hasPublicationYear "2014" @default.
• W2557864216 type Work @default.
• W2557864216 sameAs 2557864216 @default.
• W2557864216 citedByCount "0" @default.
• W2557864216 crossrefType "journal-article" @default.
• W2557864216 hasAuthorship W2557864216A5001646801 @default.
• W2557864216 hasAuthorship W2557864216A5008157848 @default.
• W2557864216 hasAuthorship W2557864216A5010717307 @default.
• W2557864216 hasAuthorship W2557864216A5014184551 @default.
• W2557864216 hasAuthorship W2557864216A5037368786 @default.
• W2557864216 hasAuthorship W2557864216A5040328429 @default.
• W2557864216 hasAuthorship W2557864216A5061692821 @default.
• W2557864216 hasAuthorship W2557864216A5070132319 @default.
• W2557864216 hasAuthorship W2557864216A5074721836 @default.
• W2557864216 hasConcept C112705442 @default.
• W2557864216 hasConcept C126322002 @default.
• W2557864216 hasConcept C126894567 @default.
• W2557864216 hasConcept C141071460 @default.
• W2557864216 hasConcept C2776694085 @default.
• W2557864216 hasConcept C2776755627 @default.
• W2557864216 hasConcept C2777288759 @default.
• W2557864216 hasConcept C2779263901 @default.
• W2557864216 hasConcept C2780272996 @default.
• W2557864216 hasConcept C2911091166 @default.
• W2557864216 hasConcept C71924100 @default.
• W2557864216 hasConcept C90924648 @default.
• W2557864216 hasConcept C98274493 @default.
• W2557864216 hasConceptScore W2557864216C112705442 @default.
• W2557864216 hasConceptScore W2557864216C126322002 @default.
• W2557864216 hasConceptScore W2557864216C126894567 @default.
• W2557864216 hasConceptScore W2557864216C141071460 @default.
• W2557864216 hasConceptScore W2557864216C2776694085 @default.
• W2557864216 hasConceptScore W2557864216C2776755627 @default.
• W2557864216 hasConceptScore W2557864216C2777288759 @default.
• W2557864216 hasConceptScore W2557864216C2779263901 @default.
• W2557864216 hasConceptScore W2557864216C2780272996 @default.
• W2557864216 hasConceptScore W2557864216C2911091166 @default.
• W2557864216 hasConceptScore W2557864216C71924100 @default.
• W2557864216 hasConceptScore W2557864216C90924648 @default.
• W2557864216 hasConceptScore W2557864216C98274493 @default.
• W2557864216 hasLocation W25578642161 @default.
• W2557864216 hasOpenAccess W2557864216 @default.
• W2557864216 hasPrimaryLocation W25578642161 @default.
• W2557864216 hasRelatedWork W2143572023 @default.
• W2557864216 hasRelatedWork W2401672012 @default.
• W2557864216 hasRelatedWork W2519736008 @default.
• W2557864216 hasRelatedWork W2556280457 @default.
• W2557864216 hasRelatedWork W2556667196 @default.
• W2557864216 hasRelatedWork W2557949783 @default.
• W2557864216 hasRelatedWork W2559903373 @default.
• W2557864216 hasRelatedWork W2565108951 @default.
• W2557864216 hasRelatedWork W2573761336 @default.
• W2557864216 hasRelatedWork W2588528479 @default.
• W2557864216 hasRelatedWork W2589310070 @default.
• W2557864216 hasRelatedWork W2912805204 @default.
• W2557864216 hasRelatedWork W2972799950 @default.
• W2557864216 hasRelatedWork W2975501169 @default.
• W2557864216 hasRelatedWork W2979305352 @default.
• W2557864216 hasRelatedWork W2979429674 @default.
• W2557864216 hasRelatedWork W2979826484 @default.
• W2557864216 hasRelatedWork W2991699855 @default.
• W2557864216 hasRelatedWork W3031895819 @default.
• W2557864216 hasRelatedWork W3180209262 @default.
• W2557864216 isParatext "false" @default.
• W2557864216 isRetracted "false" @default.
• W2557864216 magId "2557864216" @default.
• W2557864216 workType "article" @default.